Skip to main content

Helixgate

Skip to main content

Helixgate

Uncategorized

Biogen validated the Alzheimer’s tau theory. CEO Viehbacher still isn’t betting the store

Biogen validated the Alzheimer’s tau theory. CEO Viehbacher still isn’t betting the store

Published

on

With so many unknowns, Biogen is carefully eyeing its next-gen Alzheimer’s treatment diranersen as a high-risk, high-reward project with the potential for a major payout around 2030.​ ​Read More

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Uncategorized

FTC sues Hims & Hers over alleged privacy violations, deceptive billing practices

Regulators say the telehealth company illegally shared patients’ health data with advertisers and misled its customers. Hims & Hers hit back, calling the claims “baseless.”

Read More

Published

on

Regulators say the telehealth company illegally shared patients’ health data with advertisers and misled its customers. Hims & Hers hit back, calling the claims “baseless.”

Read More

Continue Reading

Uncategorized

BMS’ ‘big beat’ clouded by Cobenfy, heart disease data delays

Published

on

Strong quarterly results are prompting Bristol Myers Squibb to lift its 2026 outlook, though the company is facing another delay for key Cobenfy Alzheimer’s data and a pushed-back readout for milvexian.

Continue Reading

Uncategorized

Regeneron’s ‘aversion’ to M&A questioned as bumper Q2 builds war chest

Published

on

Calls for Regeneron to step up dealmaking have intensified as the company has established an $18 billion cash pile and suffered clinical trial setbacks.

Continue Reading
Advertisement

Trending